Targeted suppression of autoreactive CD8+ T-cell activation using blocking anti-CD8 antibodiesMathew Clement, Linda Wooldridge, James E. McLaren et al.|Scientific Reports|2016Cited by 35
Longitudinal Characterization of Autoantibodies to the Thyrotropin Receptor (TRAb) During Alemtuzumab Therapy: Evidence that TRAb May Precede Thyroid Dysfunction by Many YearsIlaria Muller, Marian Ludgate, Mark Willis et al.|Thyroid|2018Cited by 33
Meeting abstracts from the 64th British Thyroid Association Annual MeetingLuigi Bartalena, Krishna Chatterjee, Eric Fliers et al.|Thyroid Research|2017Cited by 3
Autoreactive CD8+ T-cells are highly dependent on CD8 for activation and as such targeting CD8 is an effective way of blocking autoreactive CD8+ T-cell activationLinda Wooldridge, Matthew Clement, D.A.L. Morgan et al.|The Journal of Immunology|2017Cited by 0